Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.

Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.

Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.

Alyssa Eisenberg, PharmD, discusses key industry challenges and developments as community pharmacists continue to impact patient outcomes across the US.

Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.

Shantel Upshaw Houston shares tips to prevent burnout, explains how pharmacists fill gaps in care, and urges midcareer peers to mentor students.

Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.